Clinical characteristics of patients who received IL-2 (n = 14)
| Characteristic . | No. of patients . |
|---|---|
| Sex | |
| Male | 5 |
| Female | 9 |
| Diagnosis | |
| Acute myeloid leukemia | 5 |
| Chronic lymphocytic leukemia | 5 |
| Chronic myelogenous leukemia | 1 |
| Hodgkin lymphoma | 1 |
| Myelodysplastic syndrome | 1 |
| Non-Hodgkin lymphoma | 1 |
| Conditioning regimen | |
| Myeloablative | 7 |
| Nonmyeloablative | 7 |
| Stem cell source | |
| PBSCs | 13 |
| BM and PBSCs | 1 |
| Donor type | |
| Matched-related | 4 |
| Matched-unrelated | 7 |
| Mismatched-unrelated | 3 |
| aGVHD prophylaxis | |
| Contained sirolimus | 9 |
| Did not contain sirolimus | 5 |
| Grade 2-4 aGVHD | 5 |
| Median days to cGVHD (range) | 269 (130-483) |
| Immunosuppressive therapy at start of IL-2 treatment | |
| Prednisone | 13 |
| Sirolimus | 6 |
| Tacrolimus | 5 |
| MMF | 10 |
| Characteristic . | No. of patients . |
|---|---|
| Sex | |
| Male | 5 |
| Female | 9 |
| Diagnosis | |
| Acute myeloid leukemia | 5 |
| Chronic lymphocytic leukemia | 5 |
| Chronic myelogenous leukemia | 1 |
| Hodgkin lymphoma | 1 |
| Myelodysplastic syndrome | 1 |
| Non-Hodgkin lymphoma | 1 |
| Conditioning regimen | |
| Myeloablative | 7 |
| Nonmyeloablative | 7 |
| Stem cell source | |
| PBSCs | 13 |
| BM and PBSCs | 1 |
| Donor type | |
| Matched-related | 4 |
| Matched-unrelated | 7 |
| Mismatched-unrelated | 3 |
| aGVHD prophylaxis | |
| Contained sirolimus | 9 |
| Did not contain sirolimus | 5 |
| Grade 2-4 aGVHD | 5 |
| Median days to cGVHD (range) | 269 (130-483) |
| Immunosuppressive therapy at start of IL-2 treatment | |
| Prednisone | 13 |
| Sirolimus | 6 |
| Tacrolimus | 5 |
| MMF | 10 |
aGVHD, acute GVHD; BM, bone marrow; MMF, mycophenolate mofetil; PBSC, peripheral blood stem cell.